1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, et al. (2015) Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108.
2. Lampe B, Kroll N, Piso P (2015) Prognostic Significance of Sugarbaker’s Peritoneal Cancer Index for the Operability of Ovarian Carcinoma Int J Gynecol Cancer 25: 135-44.
3. Ledermann JA (2013) Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24: vi24–32.
4. du Bois A, Reuss A, Pujade-Lauraine E (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-Ovar) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115: 1234Y1244.
5. Luyckx M, Leblanc E, Filleron T (2012) Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a retrospective French Multicentric Study Int J Gynecol Cancer 22: 1337Y1343.
6. Ghisoni, E., Katsaros, D., Maggiorotto, F. et al. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience. J Ovarian Res 11: 42.
7. Kehoe S, Hook J, Nankivell M (2013) Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. J Clin Oncol. 2013: 31.
8. Harter P, du Bois A, Hahmann M (2006) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 13: 1702Y1710.
9. Harter P, Sehouli J (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21: 289Y295.
10. Cavaliere F, De Simone M, Virzi S (2011) Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy:Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol 37:148Y154.
11. Yonemura Y, Tsukiyama G, Miyata R (2010) Indication of peritonectomy for peritoneal dissemination. Gan To Kagaku Ryoho 37: 2306Y2311.
12. Jacquet P, Sugarbaker PH (1996) Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 15: 49Y57.
13. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Arch Gynecol Obstet 293: 695–700.
14. Prat J (2015) FIGO Committee on Gynecologic Oncology. FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol 26: 87–9.
15. Eisenkop SM, Spirtos NM, Friedman RL (2003) Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90: 390Y396.
16. Fagotti A, Ferrandina G, Fanfani F (2006) A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 13:1156Y1161.
17. Brun JL, Rouzier R, Uzan S (2008) External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score. Gynecol Oncol 110:354Y359.
18. Gilly FN, Carry PY, Sayag AC (1994) Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 41: 124Y129.
19. Japanese Research Society for Gastric Cancer (2000) The general rules for the gastric cancer study in surgery and pathology. I. Clinical classification. Jpn J Surg 11: 127Y139.
20. Verwaal VJ, van Tinteren H, van Ruth S (2010) Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 91: 739Y746.
21. Koppitsch C, Sebek M (1999) Peritoneal neoplasms:scoring systems and their significance. Interdisz Onkol 4: 12Y16.
22. Sugarbaker PH (1998) Current indications for cytoreductive surgery and intraperitoneal chemotherapy. In: Sugarbaker PH. Management of Peritoneal Surface Malignancy Using Intraperitoneal Chemotherapy and Cytoreductive Surgery. A Manual for Physicians and Nurses. Grand Rapids, MI: The Ludann Company: 1998.